LCTX vs STE · rev $9.5M vs P/E 25, rev $5.46B
Lineage Cell Therapeutics Inc (LCTX) versus STERIS plc (STE) — a side-by-side from cached financials, not a winner call.
Lineage Cell Therapeutics Inc (LCTX) is a biotechnology company listed on US.
STERIS plc (STE) is a medical devices company listed on NYSE.
Latest reported LCTX revenue for 2024-12-31 was $9.5M. Net income was -$18.6M. Revenue was up 354.9% from 2023-12-31 to 2024-12-31. LCTX currently screens at market cap $213.6M.
Latest reported STE revenue for 2025-03-31 was $5.46B. Net income was $616.1M. Revenue was up 284.6% from 2024-03-31 to 2025-03-31. STE currently screens at market cap $19.43B and trailing P/E 25.1.
LCTX currently screens at market cap $213.6M. STE currently screens at market cap $19.43B and trailing P/E 25.1.
Not investment advice. Open the LCTX and STE stock pages for the full models.
Not investment advice.